Literature DB >> 25917050

Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?

Niels Vande Casteele1, Ann Gils.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25917050     DOI： 10.1007/s10620-015-3673-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  12 in total

Review 1.  Hospitalisations and surgery in Crohn's disease.

Authors:  Charles N Bernstein; Edward V Loftus; Siew C Ng; Peter L Lakatos; Bjorn Moum
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

2.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

3.  ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

Authors:  Silvio Danese; Fernando Gomollon
Journal:  J Crohns Colitis       Date:  2013-04-25       Impact factor: 9.071

4.  A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.

Authors:  R Khanna; G Zou; G D'Haens; B G Feagan; W J Sandborn; M K Vandervoort; R L Rolleri; E Bortey; C Paterson; W P Forbes; B G Levesque
Journal:  Aliment Pharmacol Ther       Date:  2014-10-27       Impact factor: 8.171

5.  Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Authors:  Niels Vande Casteele; Ann Gils; Sharat Singh; Linda Ohrmund; Scott Hauenstein; Paul Rutgeerts; Séverine Vermeire
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

6.  Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.

Authors:  Casper Steenholdt; Jørn Brynskov; Ole Ø Thomsen; Lars K Munck; Jan Fallingborg; Lisbet A Christensen; Gitte Pedersen; Jens Kjeldsen; Bent A Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark A Ainsworth
Journal:  Dig Dis Sci       Date:  2015-02-12       Impact factor: 3.199

Review 7.  Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

Authors:  Javier P Gisbert; Julián Panés
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

8.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

9.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Authors:  Casper Steenholdt; Jørn Brynskov; Ole Østergaard Thomsen; Lars Kristian Munck; Jan Fallingborg; Lisbet Ambrosius Christensen; Gitte Pedersen; Jens Kjeldsen; Bent Ascanius Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark Andrew Ainsworth
Journal:  Gut       Date:  2013-07-22       Impact factor: 23.059

Review 10.  A review of CT-P13: an infliximab biosimilar.

Authors:  Kate McKeage
Journal:  BioDrugs       Date:  2014-06       Impact factor: 5.807
View more
  7 in total

1.  Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.

Authors:  Adam Frymoyer; Travis L Piester; K T Park
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-05       Impact factor: 2.839

2.  Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease.

Authors:  Konstantinos Papamichael; Ravy K Vajravelu; Byron P Vaughn; Mark T Osterman; Adam S Cheifetz
Journal:  J Crohns Colitis       Date:  2018-06-28       Impact factor: 9.071

Review 3.  Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Authors:  Cody J Peer; Daniel A Goldstein; Jennifer C Goodell; Ryan Nguyen; William D Figg; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2020-06-11       Impact factor: 3.716

4.  Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.

Authors:  Giulia Roda; Bindia Jharap; Narula Neeraj; Jean-Frederic Colombel
Journal:  Clin Transl Gastroenterol       Date:  2016-01-07       Impact factor: 4.488

5.  Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors:  Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal:  Clin Lung Cancer       Date:  2020-06-05       Impact factor: 4.785

Review 6.  Recent advances in understanding and managing pediatric inflammatory bowel disease.

Authors:  Bhaskar Gurram; Ashish S Patel
Journal:  F1000Res       Date:  2019-12-13

Review 7.  Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?

Authors:  Anne S Strik; Yow-Ming C Wang; Laura E Ruff; William Yashar; Bradley T Messmer; Diane R Mould
Journal:  AAPS J       Date:  2018-09-05       Impact factor: 4.009
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.